Search
for
Sort by
Research
360-390 / 1000+ resultsresearch Meeting Announcement
research Calendar
research No increased risk of alopecia in ankylosing spondylitis patients: A population‐based cohort study in Taiwan
People with ankylosing spondylitis in Taiwan don't have a higher chance of getting alopecia.
research Awareness, Beliefs, and Psychological Impact of Patients with Alopecia Areata in Saudi Arabia: A Multi-Center Study
Patients with alopecia areata in Saudi Arabia understand the condition's seriousness but still face significant psychological challenges.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research General practitioners’ knowledge and practices related to alopecia areata in Qassim region, Saudi Arabia
General practitioners in Qassim have satisfactory knowledge of alopecia areata but need more education to address gaps and misconceptions.
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research Issue Information
research rwSALT: a regrowth-weighted SALT score providing direct pixel-level measurement rather than visual estimation
rwSALT provides precise hair regrowth measurement from scalp photos.
research Issue Information
research Issue Information
research Issue Information
research 706 Predictive modeling of patient response to JAK/STAT inhibitors and dynamic patient-matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
research Adalimumab improves health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS): Results from the first 12 weeks of PIONEER II
Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.